Tauroursodeoxycholic acid for the treatment of chronic hepatitis

A multicentre dose-response study

Andrea Crosignani, Pier Maria Battezzati, Cristina Cestari, Roberto Stabilini, Dario Conte, Francesco Zappalà, Annarosa Floreani, Giuseppe Montalto, Maurizio Soresi, Alberto Notarbartolo, Elisabetta Buscarini, Luigi Buscarini, Giampiero Buongiorno, Onofrio Giuseppe Manghisi, Mauro Podda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P <0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P <0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P <0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.

Original languageEnglish
Pages (from-to)10-19
Number of pages10
JournalHepatology Research
Volume13
Issue number1
Publication statusPublished - Dec 1998

Fingerprint

Chronic Hepatitis
Therapeutics
Ursodeoxycholic Acid
gamma-Glutamyltransferase
Transaminases
Alanine Transaminase
Liver Diseases
Chronic Disease
tauroursodeoxycholic acid
Serum

Keywords

  • Bile acids
  • Chronic hepatitis
  • Dose-response relationship
  • Liver disease
  • Tauroursodeoxycholic acid
  • Therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Crosignani, A., Battezzati, P. M., Cestari, C., Stabilini, R., Conte, D., Zappalà, F., ... Podda, M. (1998). Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A multicentre dose-response study. Hepatology Research, 13(1), 10-19.

Tauroursodeoxycholic acid for the treatment of chronic hepatitis : A multicentre dose-response study. / Crosignani, Andrea; Battezzati, Pier Maria; Cestari, Cristina; Stabilini, Roberto; Conte, Dario; Zappalà, Francesco; Floreani, Annarosa; Montalto, Giuseppe; Soresi, Maurizio; Notarbartolo, Alberto; Buscarini, Elisabetta; Buscarini, Luigi; Buongiorno, Giampiero; Manghisi, Onofrio Giuseppe; Podda, Mauro.

In: Hepatology Research, Vol. 13, No. 1, 12.1998, p. 10-19.

Research output: Contribution to journalArticle

Crosignani, A, Battezzati, PM, Cestari, C, Stabilini, R, Conte, D, Zappalà, F, Floreani, A, Montalto, G, Soresi, M, Notarbartolo, A, Buscarini, E, Buscarini, L, Buongiorno, G, Manghisi, OG & Podda, M 1998, 'Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A multicentre dose-response study', Hepatology Research, vol. 13, no. 1, pp. 10-19.
Crosignani A, Battezzati PM, Cestari C, Stabilini R, Conte D, Zappalà F et al. Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A multicentre dose-response study. Hepatology Research. 1998 Dec;13(1):10-19.
Crosignani, Andrea ; Battezzati, Pier Maria ; Cestari, Cristina ; Stabilini, Roberto ; Conte, Dario ; Zappalà, Francesco ; Floreani, Annarosa ; Montalto, Giuseppe ; Soresi, Maurizio ; Notarbartolo, Alberto ; Buscarini, Elisabetta ; Buscarini, Luigi ; Buongiorno, Giampiero ; Manghisi, Onofrio Giuseppe ; Podda, Mauro. / Tauroursodeoxycholic acid for the treatment of chronic hepatitis : A multicentre dose-response study. In: Hepatology Research. 1998 ; Vol. 13, No. 1. pp. 10-19.
@article{679a84fc768142a9b093d14b5e02676f,
title = "Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A multicentre dose-response study",
abstract = "Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P <0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P <0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P <0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.",
keywords = "Bile acids, Chronic hepatitis, Dose-response relationship, Liver disease, Tauroursodeoxycholic acid, Therapy",
author = "Andrea Crosignani and Battezzati, {Pier Maria} and Cristina Cestari and Roberto Stabilini and Dario Conte and Francesco Zappal{\`a} and Annarosa Floreani and Giuseppe Montalto and Maurizio Soresi and Alberto Notarbartolo and Elisabetta Buscarini and Luigi Buscarini and Giampiero Buongiorno and Manghisi, {Onofrio Giuseppe} and Mauro Podda",
year = "1998",
month = "12",
language = "English",
volume = "13",
pages = "10--19",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Tauroursodeoxycholic acid for the treatment of chronic hepatitis

T2 - A multicentre dose-response study

AU - Crosignani, Andrea

AU - Battezzati, Pier Maria

AU - Cestari, Cristina

AU - Stabilini, Roberto

AU - Conte, Dario

AU - Zappalà, Francesco

AU - Floreani, Annarosa

AU - Montalto, Giuseppe

AU - Soresi, Maurizio

AU - Notarbartolo, Alberto

AU - Buscarini, Elisabetta

AU - Buscarini, Luigi

AU - Buongiorno, Giampiero

AU - Manghisi, Onofrio Giuseppe

AU - Podda, Mauro

PY - 1998/12

Y1 - 1998/12

N2 - Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P <0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P <0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P <0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.

AB - Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P <0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P <0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P <0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.

KW - Bile acids

KW - Chronic hepatitis

KW - Dose-response relationship

KW - Liver disease

KW - Tauroursodeoxycholic acid

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0032415992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032415992&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 10

EP - 19

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 1

ER -